These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35377133)

  • 21. Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.
    Felton TW; Roberts JA; Lodise TP; Van Guilder M; Boselli E; Neely MN; Hope WW
    Antimicrob Agents Chemother; 2014 Jul; 58(7):4094-102. PubMed ID: 24798288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas aeruginosa.
    Cojutti PG; Morandin E; Baraldo M; Pea F
    Int J Antimicrob Agents; 2021 Oct; 58(4):106408. PubMed ID: 34314808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini-review and population pharmacokinetic analysis.
    Selig DJ; DeLuca JP; Chung KK; Pruskowski KA; Livezey JR; Nadeau RJ; Por ED; Akers KS
    J Clin Pharm Ther; 2022 Aug; 47(8):1091-1102. PubMed ID: 35352374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.
    Roger C; Cotta MO; Muller L; Wallis SC; Lipman J; Lefrant JY; Roberts JA
    Int J Antimicrob Agents; 2017 Aug; 50(2):227-231. PubMed ID: 28689876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients.
    Alobaid AS; Wallis SC; Jarrett P; Starr T; Stuart J; Lassig-Smith M; Mejia JL; Roberts MS; Roger C; Udy AA; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements.
    Ulldemolins M; Martín-Loeches I; Llauradó-Serra M; Fernández J; Vaquer S; Rodríguez A; Pontes C; Calvo G; Torres A; Soy D
    J Antimicrob Chemother; 2016 Jun; 71(6):1651-9. PubMed ID: 26869692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis.
    Kuti JL; Nightingale CH; Quintiliani R; Nicolau D
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):51-7. PubMed ID: 12376031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beta-lactam antibiotic concentrations in critically ill patients with standard and adjusted dosages: A prospective observational study.
    Areskog Lejbman I; Torisson G; Resman F; Sjövall F
    Acta Anaesthesiol Scand; 2024 Apr; 68(4):530-537. PubMed ID: 38407447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variability of piperacillin concentrations in relation to tazobactam concentrations in critically ill patients.
    Zander J; Döbbeler G; Nagel D; Scharf C; Huseyn-Zada M; Jung J; Frey L; Vogeser M; Zoller M
    Int J Antimicrob Agents; 2016 Oct; 48(4):435-9. PubMed ID: 27476810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections.
    Chen R; Qian Q; Sun MR; Qian CY; Zou SL; Wang ML; Wang LY
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):363-72. PubMed ID: 25894901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration.
    Varghese JM; Jarrett P; Boots RJ; Kirkpatrick CM; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2014 Apr; 43(4):343-8. PubMed ID: 24612982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants.
    Chen Y; Lu J; Dong M; Wu D; Zhu Y; Li Q; Chen C; Li Z
    Eur J Clin Pharmacol; 2016 Dec; 72(12):1479-1488. PubMed ID: 27644691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?
    Öbrink-Hansen K; Juul RV; Storgaard M; Thomsen MK; Hardlei TF; Brock B; Kreilgaard M; Gjedsted J
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7018-26. PubMed ID: 26349823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients.
    Shea KM; Cheatham SC; Wack MF; Smith DW; Sowinski KM; Kays MB
    Int J Antimicrob Agents; 2009 Nov; 34(5):429-33. PubMed ID: 19726163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
    Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients.
    Chung EK; Cheatham SC; Fleming MR; Healy DP; Shea KM; Kays MB
    J Clin Pharmacol; 2015 Aug; 55(8):899-908. PubMed ID: 25823963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population Pharmacokinetics of Piperacillin/Tazobactam Across the Adult Lifespan.
    Hemmersbach-Miller M; Balevic SJ; Winokur PL; Landersdorfer CB; Gu K; Chan AW; Cohen-Wolkowiez M; Conrad T; An G; Kirkpatrick CMJ; Swamy GK; Walter EB; Schmader KE
    Clin Pharmacokinet; 2023 Jan; 62(1):127-139. PubMed ID: 36633812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Piperacillin-tazobactam dosing in anuric acute kidney injury patients receiving continuous renal replacement therapy.
    Rungkitwattanakul D; Charoensareerat T; Chaichoke E; Rakamthong T; Srisang P; Pattharachayakul S; Srisawat N; Chaijamorn W
    Semin Dial; 2023; 36(6):468-476. PubMed ID: 36807546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function.
    Thabit AK; Grupper M; Nicolau DP; Kuti JL
    J Pharm Pract; 2017 Dec; 30(6):593-599. PubMed ID: 29121839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetics of piperacillin in critically ill children including those undergoing continuous kidney replacement therapy.
    Butragueño-Laiseca L; Marco-Ariño N; Troconiz IF; Grau S; Campillo N; García X; Padilla B; Fernández SN; Slöcker M; Santiago MJ
    Clin Microbiol Infect; 2022 Sep; 28(9):1287.e9-1287.e15. PubMed ID: 35390523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.